12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

Completed · Phase 2/Phase 3

Conditions studied: Dyslipidemia

In brief

The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia

Key facts

Study ID

NCT00664859

Run by

Veloxis Pharmaceuticals

People needed

140

Starts

2007-10-01

Expected to finish

2009-02-01

Last updated by the study team

2020-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has successfully completed the double-blind study (LCP-AtorFen-2001; NCT00504829).
• Subject has confirmed his or her willingness to participate in this study after being informed of all aspects of the study by voluntarily signing and dating an informed consent form in accordance with Good Clinical Practice (GCP).

You may not qualify if…

• Study drug compliance <70% in the double-blind study.
• Any ongoing serious adverse event, or any ongoing non-serious moderate or severe adverse event from the double-blind study that is rated as possibly, probably or definitely related to study drug.
• Resting blood pressure >/=160 mm Hg systolic and/or >/=100 mm Hg diastolic.
• Symptoms of unexplained muscle pain, tenderness or weakness (i.e., signs indicative of possible myopathy), or any diagnosis of myopathy or rhabdomyolysis.
• Any clinically significant change in physical exam or electrocardiogram from Visit 2 to Visit 6 of the double-blind study.
• Any clinically significant change from Visit 1 to Visit 6 of the double-blind study in medical history including, but not limited to: a diagnosis of insulin-dependent diabetes mellitus (DM); poorly controlled DM; poorly controlled hypertension; significant renal, pulmonary, hepatic, biliary, or gastrointestinal disease; cancer (except non-melanoma skin cancer); and epilepsy.
• Unwilling to abstain from medications, supplements, ingredients and herbal therapies that were excluded in the double-blind study and continue to be excluded in the open-label study.
• Women who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential (not surgically sterilized between menarche and menopause) who are not using a medically approved method of contraception.
• Other exclusion conditions might apply.

Where it is running

• Radiant Research, 515 N State St, Suite 2700 — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.